1. Home
  2. COEP vs PMN Comparison

COEP vs PMN Comparison

Compare COEP & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • PMN
  • Stock Information
  • Founded
  • COEP 2017
  • PMN 2004
  • Country
  • COEP United States
  • PMN Canada
  • Employees
  • COEP N/A
  • PMN N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • COEP Health Care
  • PMN Health Care
  • Exchange
  • COEP Nasdaq
  • PMN Nasdaq
  • Market Cap
  • COEP 32.4M
  • PMN 29.8M
  • IPO Year
  • COEP N/A
  • PMN N/A
  • Fundamental
  • Price
  • COEP $12.45
  • PMN $0.95
  • Analyst Decision
  • COEP
  • PMN
  • Analyst Count
  • COEP 0
  • PMN 0
  • Target Price
  • COEP N/A
  • PMN N/A
  • AVG Volume (30 Days)
  • COEP 111.8K
  • PMN 43.9K
  • Earning Date
  • COEP 03-25-2025
  • PMN 03-31-2025
  • Dividend Yield
  • COEP N/A
  • PMN N/A
  • EPS Growth
  • COEP N/A
  • PMN N/A
  • EPS
  • COEP N/A
  • PMN N/A
  • Revenue
  • COEP N/A
  • PMN N/A
  • Revenue This Year
  • COEP N/A
  • PMN N/A
  • Revenue Next Year
  • COEP N/A
  • PMN N/A
  • P/E Ratio
  • COEP N/A
  • PMN N/A
  • Revenue Growth
  • COEP N/A
  • PMN N/A
  • 52 Week Low
  • COEP $2.31
  • PMN $0.87
  • 52 Week High
  • COEP $13.70
  • PMN $2.61
  • Technical
  • Relative Strength Index (RSI)
  • COEP 63.21
  • PMN 52.16
  • Support Level
  • COEP $8.65
  • PMN $0.88
  • Resistance Level
  • COEP $12.95
  • PMN $1.03
  • Average True Range (ATR)
  • COEP 1.64
  • PMN 0.06
  • MACD
  • COEP -0.16
  • PMN 0.00
  • Stochastic Oscillator
  • COEP 75.25
  • PMN 46.67

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: